Your Health and Fitness Partner: Androxal & FitHub

We are also excited to expand our scope by including valuable information on Androxal, a potent medication beneficial in various medical conditions. This remarkable drug, derived from the testosterone molecule, has made its mark significantly in the field of endocrinology. Patients and medical professionals can rely on our comprehensive, unbiased, and scientifically grounded content on Androxal for gaining a robust understanding of its uses, side effects, and the latest studies related to it. We understand the necessity of accurate information when it comes to medication. Our newly launched section dedicated to Androxal aims at not only educating the readers about its nuances but also at contributing beneficially to their wellbeing. Stay tuned for insightful articles unraveling the potential of Androxal in medical science.

Sitemap | Policies | Feedback    
 About the Journal
Editorial Board
Journal Subscription
Instructions for Authors
E-mail Alerts
Forthcoming Events
Advertise with Us
Contact Us
 
Article Options
FULL TEXT
ABSTRACT
PDF
Printer Friendly Version
Search Pubmed for
Search Google Scholar for
Article Statistics
Bookmark and Share
 
Serum pepsinogen I and II levels in various gastric disorders with special reference to their use as a screening test for carcinoma stomach
 
Parthasarathy G1, Maroju NK1, Kate V1, Ananthakrishnan N1, Sridhar MG2
Director-Professor and Head,
Deptartment of Surgery,
JIPMER, Pondicherry, India;


Corresponding Author
: Prof. N. Ananthakrishnan
Email:n.ananthk@gmail.com, ananthsa@satyam.net.in


Abstract

Introduction: The role of serum pepsinogen in the diagnosis of gastric carcinoma is well established.  Its role in other common upper alimentary disorders has not been widely studied.  The aim of this study was to describe the effect of various gastric disorders on the levels of pepsinogen I, pepsinogen II and pepsinogen I/II ratio, with an emphasis on the diagnosis of carcinoma stomach in the South Indian population.

Methods:  A total of 210 patients in seven groups, including one control group, were studied.  The groups included patients with carcinoma stomach, Helicobacter pylori gastritis, peptic ulcer, portal hypertensive gastropathy, non-ulcer dyspepsia and erosive gastritis.  Serum pepsinogen I, pepsinogen II and pepsinogen I/II ratio were estimated using an enzyme-linked immunosorbent assay technique.

Results: Patients with carcinoma of the stomach, when compared with controls, had a significantly lower pepsinogen I level (87.2 µg/L vs. 158.1 µg/L, p=0.0002) and pepsinogen I/II ratio (4.3 vs. 7.2, p = 0.0001).  No significant change in pepsinogen levels occurred in the other groups.  The cut-off levels of pepsinogen I (115.3 µg/L) and pepsinogen I/II ratio (6.2), determined by THE ROC curve, when applied in parallel provided a sensitivity of 97% and a negative predictive value of 91.4% for the diagnosis of carcinoma stomach.  When the tests were applied in parallel, the likelihood ratio of a negative test was 0.06, indicating that  individuals without carcinoma stomach were 16 times more likely to have a negative test than those with carcinoma. This fulfilled the essential prerequisites of an ideal screening test.

Conclusion: Serum pepsinogen estimation is a useful diagnostic tool in the diagnosis of carcinoma stomach.  The significance of serum pepsinogen level in portal hypertensive gastropathy, non-ulcer dyspepsia, peptic ulcer, Helicobacter pylori gastritis and erosive gastritis was not established.